Katrina Walker

507 total citations
18 papers, 275 citations indexed

About

Katrina Walker is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Katrina Walker has authored 18 papers receiving a total of 275 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 9 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in Katrina Walker's work include Multiple Myeloma Research and Treatments (11 papers), Protein Degradation and Inhibitors (8 papers) and Stroke Rehabilitation and Recovery (3 papers). Katrina Walker is often cited by papers focused on Multiple Myeloma Research and Treatments (11 papers), Protein Degradation and Inhibitors (8 papers) and Stroke Rehabilitation and Recovery (3 papers). Katrina Walker collaborates with scholars based in United Kingdom, Australia and United States. Katrina Walker's co-authors include Ingrid Rosbergen, Alana Campbell, Rohan Grimley, Kathryn S. Hayward, Sandra Brauer, Heidi Janssen, Sarah Brown, Martin Kaiser, Andrew Hall and Gordon Cook and has published in prestigious journals such as Journal of Clinical Oncology, Blood and BMJ.

In The Last Decade

Katrina Walker

18 papers receiving 271 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Katrina Walker United Kingdom	9	114	104	67	62	40	18	275
Johnny Nijm Sweden	9	32 0.3×	60 0.6×	65 1.0×	12 0.2×	65 1.6×	10	424
Miklós Szólics United Arab Emirates	12	26 0.2×	45 0.4×	26 0.4×	7 0.1×	15 0.4×	42	310
Thorsten Schultheiß Germany	11	23 0.2×	35 0.3×	27 0.4×	23 0.4×	54 1.4×	17	342
C. M. Tench United Kingdom	5	78 0.7×	27 0.3×	10 0.1×	21 0.3×	32 0.8×	7	428
Ryan Eckert United States	12	69 0.6×	70 0.7×	72 1.1×	14 0.2×	17 0.4×	32	379
Ryan Fischer United States	11	10 0.1×	138 1.3×	28 0.4×	11 0.2×	11 0.3×	27	351
Adeel Nasir United States	4	46 0.4×	37 0.4×	31 0.5×	6 0.1×	35 0.9×	6	428
Laura Bazzichi Italy	10	48 0.4×	43 0.4×	8 0.1×	9 0.1×	15 0.4×	18	346
Britta Strömbeck Sweden	11	106 0.9×	8 0.1×	41 0.6×	31 0.5×	26 0.7×	14	429
Katsunori Tsuji Japan	11	12 0.1×	31 0.3×	84 1.3×	35 0.6×	18 0.5×	32	349

Countries citing papers authored by Katrina Walker

Since Specialization

Citations

This map shows the geographic impact of Katrina Walker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katrina Walker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katrina Walker more than expected).

Fields of papers citing papers by Katrina Walker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katrina Walker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katrina Walker. The network helps show where Katrina Walker may publish in the future.

Co-authorship network of co-authors of Katrina Walker

This figure shows the co-authorship network connecting the top 25 collaborators of Katrina Walker. A scholar is included among the top collaborators of Katrina Walker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katrina Walker. Katrina Walker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Kaiser, Martin, Andrew Hall, Katrina Walker, et al.. (2023). Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma. Journal of Clinical Oncology. 41(23). 3945–3955. 54 indexed citations

Walker, Katrina, Samantha Hinsley, Anthony J. Chalmers, et al.. (2022). Implementation of the Time-to-Event Continuous Reassessment Method Design in a Phase I Platform Trial Testing Novel Radiotherapy-Drug Combinations—CONCORDE. JCO Precision Oncology. 6(6). e2200133–e2200133. 2 indexed citations

Homer, Victoria, Christina Yap, Simon Bond, et al.. (2022). Early phase clinical trials extension to guidelines for the content of statistical analysis plans. BMJ. 376. e068177–e068177. 17 indexed citations

Auner, Holger W., Sarah Brown, Katrina Walker, et al.. (2022). Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results. Blood Cancer Journal. 12(4). 52–52. 10 indexed citations

Brown, Sarah, Samantha Hinsley, Louise Flanagan, et al.. (2021). MUK nine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia. BMJ Open. 11(3). e046225–e046225. 17 indexed citations

Kaiser, Martin, Andrew Hall, Katrina Walker, et al.. (2021). Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): Results of the UK optimum/MUKnine trial.. Journal of Clinical Oncology. 39(15_suppl). 8001–8001. 11 indexed citations

Kaiser, Martin, Andrew Hall, Katrina Walker, et al.. (2021). Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, Dexamethasone (Dara-CVRd), V-Augmented Autologous Stem Cell Transplant (V-ASCT) and Dara-Vrd Consolidation in Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL) Compared with Myeloma XI/XI+ Trial Treatment for Uhir MM: The UK Optimum/Muknine Trial. Blood. 138(Supplement 1). 465–465. 8 indexed citations

Kaiser, Martin, Andrew Hall, Katrina Walker, et al.. (2021). OAB-012: Depth of response and MRD in newly diagnosed ultra high-risk myeloma and plasma cell leukemia treated with Dara-CVRd and V-MEL ASCT: results of the molecularly stratified UK OPTIMUM/MUKnine trial. Clinical Lymphoma Myeloma & Leukemia. 21. S8–S8. 1 indexed citations

Hinsley, Samantha, Katrina Walker, Lucy Bailey, et al.. (2020). The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor. Trials. 21(1). 826–826. 3 indexed citations

10.

Jenner, Matthew, Amy L. Sherborne, Andrew Hall, et al.. (2019). Molecular Treatment Stratification for Newly Diagnosed High-Risk Myeloma, Including Plasma Cell Leukemia - Feasibility Results of the Ukmra Optimum: MUK9 Trial (NCT03188172). Blood. 134(Supplement_1). 3162–3162. 1 indexed citations

11.

Hall, Andrew, Amy L. Sherborne, Katrina Walker, et al.. (2019). Prognostic Molecular Stratification in Relapsed/Refractory Multiple Myeloma - Results of the Pomalidomide Mukseven (NCT02406222) Biomarker Trial. Blood. 134(Supplement_1). 4327–4327. 4 indexed citations

12.

Hall, Andrew, Katrina Walker, Amy L. Sherborne, et al.. (2018). Cyclophosphamide, Pomalidomide and Dexamethasone Significantly Improves Response over Poma/Dex in Relapsed/Refractory Myeloma Patients Previously Treated with Cyclophosphamide Combination Therapy - Initial Results of the Randomised Multicentre Mukseven Trial. Blood. 132(Supplement 1). 3274–3274. 2 indexed citations

13.

Hall, Andrew, Katrina Walker, Amy L. Sherborne, et al.. (2018). Cyclophosphamide Exerts Significant Immunomodulatory Function in Myeloma Patients Treated with Pomalidomide and Dexamethasone. Blood. 132(Supplement 1). 4482–4482. 8 indexed citations

14.

Rosbergen, Ingrid, Rohan Grimley, Kathryn S. Hayward, et al.. (2017). Embedding an enriched environment in an acute stroke unit increases activity in people with stroke: a controlled before–after pilot study. Clinical Rehabilitation. 31(11). 1516–1528. 92 indexed citations

15.

Rosbergen, Ingrid, Rohan Grimley, Kathryn S. Hayward, et al.. (2016). The effect of an enriched environment on activity levels in people with stroke in an acute stroke unit: protocol for a before-after pilot study. Pilot and Feasibility Studies. 2(1). 36–36. 19 indexed citations

16.

McClurg, Doreen, et al.. (2016). Abdominal Massage for the Relief of Constipation in People with Parkinson’s: A Qualitative Study. Parkinson s Disease. 2016. 1–10. 24 indexed citations

17.

Barnett, Gillian C., Richard Benson, Sarah Jefferies, et al.. (2015). Starting priority radiotherapy treatments more quickly. Clinical Oncology. 27. S8–S8. 1 indexed citations

18.

Rosbergen, Ingrid, Rohan Grimley, Kathryn S. Hayward, et al.. (2014). Feasibility of creating an enriched environment and subsequent impact on activity levels for stroke patients in an acute stroke unit: A study protocol. International Journal of Stroke. 9. 37–38. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact